Beta 2 Microglobulin

High beta-2 microglobulin (β2M) indicates increased cell turnover or reduced kidney clearance. It commonly reflects impaired renal function, active inflammation, or certain blood cancers (such as multiple myeloma or lymphoma). β2M helps with staging/prognosis in hematologic malignancies and monitoring kidney/disease status. Elevated levels prompt further evaluation—renal tests, infection/inflammation work-up, and hematologic assessment to determine the cause.

Beta-2 microglobulin (β2M) is commonly elevated in multiple myeloma and in many lymphoproliferative cancers such as chronic lymphocytic leukemia and non‑Hodgkin lymphoma. It’s used as a prognostic and staging marker—particularly in multiple myeloma—because levels correlate with tumor burden. Note elevations also occur with renal dysfunction and inflammatory conditions, so results must be interpreted in clinical context.

Beta‑2 microglobulin is a small protein component of MHC class I molecules on all nucleated cells; it stabilizes MHC I and helps present intracellular peptides to CD8+ T cells, enabling immune surveillance. It is freely filtered by the kidneys, so blood levels reflect renal function and may rise in kidney failure, chronic inflammation, or certain hematologic cancers, making it a useful clinical marker.

Yes. Systemic inflammation can raise serum beta-2 microglobulin by increasing production from activated immune cells and heightened cell turnover. Acute or chronic infections, autoimmune and inflammatory diseases often elevate levels. However, impaired kidney function markedly reduces clearance and is a major cause of high values, so elevated beta‑2 microglobulin should be interpreted with clinical context and renal function tests.

To lower beta‑2 microglobulin, treat underlying kidney disease and improve dialysis clearance—use high‑flux membranes or online hemodiafiltration and ensure dialysis adequacy. Reduce chronic inflammation and infections, control blood pressure and blood sugar, stop smoking, and follow nutrition guidance. Renal transplantation markedly lowers levels when appropriate. Regular monitoring and clinician‑guided medication adjustments help manage contributing factors.

β2‑microglobulin is freely filtered by the renal glomeruli and is normally almost completely reabsorbed and proteolytically degraded by proximal tubular cells, so little appears in urine. In kidney failure its blood levels rise; removal then relies on extracorporeal therapies — especially high‑flux hemodialysis or hemodiafiltration (and adsorption-capable filters) that clear middle‑molecules better than low‑flux dialysis.